Our purpose was to compare the safety andefficacy of lansoprazole 15 mg and 30 mg with placebo inpreventing recurrence in 49 patients with a history ofgastric ulcer. Within one month, 40% of patients receiving placebo experienced ulcer recurrencecompared to 0% and 7% of patients receiving lansoprazole15 mg and 30 mg, respectively. All placebo patientsbecame symptomatic, experienced ulcer recurrence or withdrew from the study by month 9. Ascompared to placebo, a significantly (P < 0.001)higher="" percentage="" of="" patients="" treated="" with="" lansoprazole15="" mg="" (83%)="" and="" lansoprazole="" 30="" mg="" (93%)="" with="" healed="" gastric="" ulcer="" disease="" remained="" healed="" at="" month12.="" of="" patients="" asymptomatic="" at="" baseline,="" 100%="" and="" 59%of="" those="" treated="" with="" lansoprazole="" 15="" mg="" and="" 30="" mg,respectively,="" remained="" asymptomatic="" at="" month="" 12.="" the="" incidence="" of="" adverse="" events="" was="" comparableamong="" the="" treatment="" groups.="" lansoprazole="" safely="" andeffectively="" reduces="" ulcer="" recurrence="" in="" patients="" with="" ahistory="" of="" gastric="" ulcer="">